Grace Therapeutics, Inc. (GRCE)

Market Cap	40.79M
Revenue (ttm)	n/a
Net Income (ttm)	-9.57M
Shares Out	13.83M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,104
Open	2.950
Previous Close	2.940
Day's Range	2.950 - 2.950
52-Week Range	1.750 - 4.965
Beta	0.91
Analysts	Strong Buy
Price Target	12.00 (+306.78%)
Earnings Date	Jun 23, 2025

About GRCE

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: GRCE
• Website: https://www.gracetx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to one analyst, the rating for GRCE stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(306.78% upside)

Analyst Consensus: Strong Buy